Porcilis PRRS vet.
ATC code
Species
Pigs.
Indications
For active immunisation of clinically healthy pigs in a PRRS virus contaminated environment, to reduce viraemia caused by infection with European strains of PRRS virus.
Specific claims
For finishing pigs, the effect of the virus on the respiratory system is most relevant. A significant improvement of rearing results (reduced morbidity due to PRRS infection, and a better daily growth and feed conversion) until the end of the fattening period was observed in vaccinated pigs during field trials, particularly in piglets vaccinated at 6 weeks of age.
For breeding pigs, the effect of the virus on the reproductive system is most relevant.
A significant improvement of the reproductive performance in PRRS virus contaminated environments and a reduction of transplacental virus transmission after challenge was observed in vaccinated pigs.
Onset of immunity: 28 days post vaccination.
Duration of immunity: 24 weeks post vaccination.
Dose to be administered and administration route
Reconstitute the vaccine with the corresponding adjuvating solvent.
|
Number of doses per vial |
Volume (ml) of solvent needed for |
|
|
intramuscular injection |
intradermal application |
|
|
10 25 50 100 |
20 50 100 200 |
2 5 10 20 |
Before reconstitution allow the solvent to reach room temperature (15 °C – 25 °C) and shake well before use.
Visual appearance after reconstitution: white suspension.
Dosage:
Intramuscular injection: 2 ml in the neck.
Intradermal application: 0.2 ml on top or to the left or right side of the neck, or along the muscles of the back, using a multi-dose needle-free injection device for intradermal application of liquids suitable to deliver a “jet-stream” volume of vaccine (0.2 ml ± 10 %) through the epidermal layers of the skin.
A small, transient, intradermal lump observed after the intradermal application is indicative of the appropriate vaccination technique.
Vaccination scheme:
A single dose is given to pigs from 2 weeks of age onwards.
| Finishing pigs: | a single vaccination is sufficient for protection until slaughter. |
| Breeding pigs: |
For gilts a (re)vaccination 2 - 4 weeks before mating is recommended. To maintain a high and homologous level of immunity, revaccination at regular intervals is recommended, either before each next gestation or at random at 4 month intervals. Pregnant sows should only be vaccinated after previous exposure to European PRRS virus. |
The vaccine may be reconstituted shortly before vaccination for simultaneous use with Porcilis M Hyo in finishing pigs from 4 weeks of age and the following instructions should be used:
| Porcilis PRRS | Porcilis M Hyo |
| 10 doses | + 20 ml |
| 25 doses | + 50 ml |
| 50 doses | + 100 ml |
| 100 doses | + 200 ml |
A single dose (2 ml) of Porcilis PRRS mixed with Porcilis M Hyo is given intramuscularly in the neck.
Use sterile syringes and needles or clean intradermal equipment.
Adverse reactions
Pigs:
|
Very common (>1 animal / 10 animals treated): |
Injection site lump.1 |
|
Rare (1 to 10 animals / 10,000 animals treated): |
Hyperthermia2, hypersensitivity reactions (including dyspnoea, hyperaemia, decubitus, muscle tremor, excitation, vomiting).3 |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Anaphylactic-type reactions.4 |
1 After intradermal vaccination a small firm injection site lump (maximum 1.5 cm in diameter) is observed and is indicative of the appropriate vaccination technique. This lump is generally seen for less than 14 days but may occasionally persist for 29 days or longer.
2 After intramuscular vaccination.
3 These signs disappear spontaneously and totally within a few minutes after vaccination.
4 Fatal outcome of anaphylactic-type reactions has been reported very rarely.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the last section of the package leaflet for respective contact details.
